NAV

Allogenic donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
Commonly known or available as Allogenic donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
DrugBank Accession Number
DB15731
Background

ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor’s cells can be given to other unrelated patients. These cells are CD362 enriched umbilical cord-derived mesenchymal stem cells (UC-MSCs); UC-MSCs share stemness markers with both embryonic stem cells (ESCs) and adult mesenchymal stem cells (MSCs); this feature allows them to be hypoimmunogenic and non-inducible for tumorigenesis.

Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties. Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • Allogeneic donor CD362 enriched human umbilical cord-derived mesenchymal stromal cells
  • ORBCEL C™
  • Orbcel-C
  • REALIST ORBCEL-C
External IDs
  • Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

The mesenchymal stem cells (MSCs) of ORBCEL-C™ act through release of factors which reduce inflammatory responses, promote blood vessel formation, and have the ability to demonstrate immunomodulatory effects.

Allogeneic UC-MSCs are also being investigated in orthopedic applications for cartilage and bone regeneration; these UC-MSCs are a valuable allogeneic source of cells as these cells are from a discarded material with virtually unlimited availability. Specifically to orthopedics, UC-MSCs have potential for treatment of chondral and osteochondral lesions, and bone defects as a universal off-the-shelf product.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Marmotti A, Mattia S, Castoldi F, Barbero A, Mangiavini L, Bonasia DE, Bruzzone M, Dettoni F, Scurati R, Peretti GM: Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells as a Potential Source for Cartilage and Bone Regeneration: An In Vitro Study. Stem Cells Int. 2017;2017:1732094. doi: 10.1155/2017/1732094. Epub 2017 Nov 16. [Article]
  2. de Witte SFH, Merino AM, Franquesa M, Strini T, van Zoggel JAA, Korevaar SS, Luk F, Gargesha M, O'Flynn L, Roy D, Elliman SJ, Newsome PN, Baan CC, Hoogduijn MJ: Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. Stem Cell Res Ther. 2017 Jun 8;8(1):140. doi: 10.1186/s13287-017-0590-6. [Article]
  3. Alfaifi M, Eom YW, Newsome PN, Baik SK: Mesenchymal stromal cell therapy for liver diseases. J Hepatol. 2018 Jun;68(6):1272-1285. doi: 10.1016/j.jhep.2018.01.030. Epub 2018 Feb 7. [Article]
  4. Zakrzewski W, Dobrzynski M, Szymonowicz M, Rybak Z: Stem cells: past, present, and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68. doi: 10.1186/s13287-019-1165-5. [Article]
  5. Technologies [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentAutoimmune Hepatitis / Sclerosing Cholangitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 19:17 / Updated at August 13, 2020 07:02